Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.33 Insider Own11.33% Shs Outstand184.14M Perf Week7.00%
Market Cap201.58M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float167.05M Perf Month21.32%
Income-61.09M PEG- EPS next Q-0.04 Inst Own18.41% Short Float / Ratio5.92% / 7.45 Perf Quarter-19.55%
Sales193.61M P/S1.04 EPS this Y37.75% Inst Trans-9.77% Short Interest9.88M Perf Half Y-2.73%
Book/sh-0.21 P/B- EPS next Y9.71% ROA-18.21% Target Price4.33 Perf Year295.56%
Cash/sh0.25 P/C4.33 EPS next 5Y- ROE-554.87% 52W Range0.27 - 1.84 Perf YTD85.44%
Dividend- P/FCF- EPS past 5Y21.17% ROI-99.37% 52W High-41.85% Beta0.92
Dividend %- Quick Ratio1.14 Sales past 5Y14.78% Gross Margin53.03% 52W Low302.86% ATR0.07
Employees205 Current Ratio1.38 Sales Q/Q-14.13% Oper. Margin-28.87% RSI (14)59.49 Volatility6.87% 8.03%
OptionableYes Debt/Eq- EPS Q/Q72.74% Profit Margin-31.56% Rel Volume0.90 Prev Close1.06
ShortableYes LT Debt/Eq- EarningsNov 08 BMO Payout- Avg Volume1.33M Price1.07
Recom1.00 SMA209.02% SMA508.96% SMA2003.81% Volume1,191,934 Change0.94%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Resumed BTIG Research Buy $4
Aug-28-23Upgrade H.C. Wainwright Neutral → Buy $3.75
May-31-23Upgrade Piper Sandler Neutral → Overweight $2 → $4
Mar-31-22Downgrade Piper Sandler Overweight → Neutral $8 → $2
Mar-31-22Downgrade Needham Buy → Hold
Mar-31-22Downgrade Mizuho Buy → Neutral $6 → $2
Mar-31-22Downgrade H.C. Wainwright Buy → Neutral $10 → $2
Mar-08-21Initiated Cantor Fitzgerald Overweight $8
Jan-29-21Downgrade JP Morgan Neutral → Underweight
Nov-14-19Reiterated Needham Buy $18 → $15
Dec-01-23 04:05PM
Nov-20-23 08:00AM
Nov-09-23 11:32AM
Nov-08-23 10:05PM
07:40AM Loading…
Nov-02-23 04:30PM
Nov-01-23 04:05PM
Oct-31-23 08:00AM
Oct-26-23 10:02AM
Oct-25-23 08:30AM
Oct-18-23 08:00AM
Oct-03-23 04:05PM
Sep-28-23 08:00AM
08:00AM Loading…
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Sep-05-23 04:05PM
Aug-31-23 06:15AM
Aug-28-23 12:18PM
Aug-25-23 10:25PM
Aug-24-23 08:00AM
Aug-23-23 04:35PM
Aug-17-23 04:05PM
Aug-10-23 05:40PM
04:30PM Loading…
Aug-01-23 04:30PM
Jul-26-23 09:40AM
Jul-19-23 07:45AM
Jul-18-23 07:45AM
Jul-06-23 06:07AM
Jul-05-23 04:05PM
Jul-04-23 07:34AM
Jun-29-23 08:00AM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-20-23 08:00AM
Jun-19-23 09:40AM
Jun-13-23 07:00AM
Jun-08-23 01:20PM
Jun-02-23 12:00PM
Jun-01-23 04:05PM
May-30-23 07:30AM
May-25-23 08:00AM
May-23-23 11:27AM
May-22-23 05:15PM
May-10-23 09:40AM
May-09-23 02:12AM
May-08-23 08:45AM
May-04-23 10:00AM
May-01-23 10:01AM
Apr-25-23 02:30PM
Apr-19-23 01:07PM
Apr-14-23 08:30AM
Apr-11-23 11:15AM
Apr-07-23 08:30AM
Apr-04-23 04:05PM
Apr-03-23 08:30AM
Mar-30-23 08:30AM
Mar-24-23 08:30AM
Mar-13-23 02:51AM
Mar-09-23 10:42PM
Mar-02-23 08:30AM
Feb-23-23 04:05PM
Feb-21-23 06:30AM
Feb-01-23 04:05PM
Jan-03-23 04:05PM
Dec-22-22 08:45AM
Dec-02-22 04:05PM
Nov-22-22 04:05PM
Nov-09-22 06:10AM
Nov-03-22 06:45PM
Nov-02-22 04:05PM
Oct-27-22 08:30AM
Oct-21-22 08:30AM
Oct-03-22 04:05PM
Sep-02-22 04:05PM
Sep-01-22 08:30AM
Aug-05-22 11:12AM
Aug-04-22 07:25PM
Aug-02-22 04:05PM
Jul-26-22 08:00AM
Jul-05-22 04:05PM
Jun-30-22 04:05PM
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dahan MichelSVP, Chief Operating OfficerMay 25Sale1.2295,478116,760574,037May 25 09:01 PM
Hadas Nicole R.SVP, Chief Legal OfficerMay 25Sale1.2263,18677,270524,344May 25 09:01 PM
Burke Steven KeithSVP, Chief Medical OfficerMay 16Sale1.0763,56767,890530,487May 18 06:20 PM
Spellman David ASVP, CFO and TreasurerMay 16Sale1.0763,56767,890446,483May 18 06:19 PM
Butler John P.CEO and PresidentMar 01Sale0.8891,86880,6141,568,872Mar 03 08:01 AM
Dahan MichelSVP, Chief Operating OfficerMar 01Sale0.8820,41217,912269,515Mar 03 08:01 AM
Burke Steven KeithSVP, Chief Medical OfficerMar 01Sale0.8814,12312,393594,054Mar 03 08:01 AM
Hadas Nicole R.SVP, Chief Legal OfficerMar 01Sale0.8813,03411,437287,530Mar 03 08:01 AM
Spellman David ASVP, CFO and TreasurerMar 01Sale0.887,2106,327510,050Mar 03 08:00 AM
Butler John P.CEO and PresidentFeb 27Sale0.8138,63231,4161,660,740Mar 01 04:07 PM
Dahan MichelSVP, Chief Operating OfficerFeb 27Sale0.8110,0908,205289,927Mar 01 04:06 PM
Spellman David ASVP, CFO and TreasurerFeb 27Sale0.817,5396,131517,260Mar 01 04:05 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 27Sale0.817,5396,131608,177Mar 01 04:06 PM
Hadas Nicole R.SVP, Chief Legal OfficerFeb 27Sale0.816,6775,430300,564Mar 01 04:05 PM